{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:59:45Z","timestamp":1783162785154,"version":"3.54.6"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Cornell University Institute of Biotechnology"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jconrel.2019.11.027","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T11:08:28Z","timestamp":1574507308000},"page":"291-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate"],"prefix":"10.1016","volume":"317","author":[{"given":"Sarah","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamanth","family":"Murundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-4915","authenticated-orcid":false,"given":"David","family":"Putnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2019.11.027_bb0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2019.11.027_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2710.2003.00487.x","article-title":"Structure\u2013activity relationship: analyses of p-glycoprotein substrates and inhibitors","volume":"28","author":"Wang","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"issue":"7","key":"10.1016\/j.jconrel.2019.11.027_bb0015","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1021\/cr9000226","article-title":"ABC efflux pump-based resistance to chemotherapy drugs","volume":"109","author":"Eckford","year":"2009","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2019.11.027_bb0020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/dmd.113.056176","article-title":"Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?","volume":"42","author":"Callaghan","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/pr.107.07109","article-title":"Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy","volume":"60","author":"Miller","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2015.12.041","article-title":"Concepts, technologies, and practices for drug delivery past the blood\u2013brain barrier to the central nervous system","volume":"240","author":"Crawford","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0091270011399574","article-title":"Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study","volume":"52","author":"O\u2019Hara","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2019.11.027_bb0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001615","article-title":"Comprehensive T wave morphology assessment in a randomized clinical study of Dofetilide, quinidine, Ranolazine, and verapamil","volume":"4","author":"Vicente","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.jconrel.2019.11.027_bb0045","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.99.4.552","article-title":"Inhibition of P-glycoprotein\u2013mediated drug transport","volume":"99","author":"Fromm","year":"1999","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jconrel.2019.11.027_bb0050","first-page":"4303","article-title":"Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drugresistant tumor cells","volume":"44","author":"Tsuruo","year":"1984","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2019.11.027_bb0055","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1200\/JCO.1994.12.9.1771","article-title":"Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial","volume":"12","author":"Wishart","year":"1994","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2019.11.027_bb0060","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00280-014-2438-4","article-title":"No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers","volume":"73","author":"Chen","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","article-title":"Pharmacology of dextromethorphan: relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use","volume":"164","author":"Taylor","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2019.11.027_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12883-016-0609-0","article-title":"PRISM II: an open-label study to assess effectiveness of dextromethorphan\/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury","volume":"16","author":"Hammond","year":"2016","journal-title":"BMC Neurol."},{"issue":"12","key":"10.1016\/j.jconrel.2019.11.027_bb0075","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jconrel.2019.11.027_bb0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.613","article-title":"The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol","volume":"56","author":"Bui","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2019.11.027_bb0085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jps.2600630615","article-title":"Fluorescence of 6-methoxyquinoline, quinine, and quinidine in aqueous media","volume":"63","author":"Schulman","year":"1974","journal-title":"J. Pharm. Sci."},{"issue":"14","key":"10.1016\/j.jconrel.2019.11.027_bb0090","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1073\/pnas.1800043115","article-title":"Monoclonal antibody targeting the \u03b2-barrel assembly machine of <em>Escherichia coli<\/em> is bactericidal","volume":"115","author":"Storek","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2019.11.027_bb0095","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01851-18","article-title":"The mechanism behind bacterial lipoprotein release: phenol-soluble modulins mediate toll-like receptor 2 activation via extracellular vesicle release from Staphylococcus aureus","volume":"9","author":"Schlatterer","year":"2018","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.jconrel.2019.11.027_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2018.02.027","article-title":"The use of fatty acids as absorption enhancer for pulmonary drug delivery","volume":"541","author":"Ghadiri","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1124\/dmd.118.083188","article-title":"Overcoming P-glycoprotein\u2013mediated drug resistance with noscapine derivatives","volume":"47","author":"Muthiah","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"51","key":"10.1016\/j.jconrel.2019.11.027_bb0110","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi011211z","article-title":"The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein","volume":"40","author":"Martin","year":"2001","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.jconrel.2019.11.027_bb0115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0022-3565(24)37960-1","article-title":"Characterization of binding properties to human p-glycoprotein: development of a [3H]verapamil radioligand-binding assay","volume":"288","author":"D\u00f6ppenschmitt","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0120","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1021\/bc5002196","article-title":"Synthesis and characterization of macromolecular rhodamine tethers and their interactions with P-glycoprotein","volume":"25","author":"Crawford","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0125","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.2741\/2882","article-title":"Polymer-drug conjugates: current status and future trends","volume":"13","author":"Greco","year":"2008","journal-title":"Front. Biosci."},{"issue":"4","key":"10.1016\/j.jconrel.2019.11.027_bb0130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrd1066","article-title":"Issues and progress with protein kinase inhibitors for cancer treatment","volume":"2","author":"Dancey","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"149","key":"10.1016\/j.jconrel.2019.11.027_bb0135","article-title":"PEG-dendron architecture influences endocytic capture and intracellular trafficking proceed","volume":"30","author":"Xyloyiannis","year":"2003","journal-title":"Int. Symp. Control. Rel. Bioact. Mater."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2014.05.012","article-title":"Interactions of anticancer drugs with biomembranes: what can we learn from model membranes?","volume":"190","author":"Bourgaux","year":"2014","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1432-1327.2000.01046.x","article-title":"Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane","volume":"267","author":"Fert\u00e9","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"7","key":"10.1016\/j.jconrel.2019.11.027_bb0150","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/S0021-9258(19)39690-5","article-title":"Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells","volume":"265","author":"Raviv","year":"1990","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0005-2736(82)90536-3","article-title":"Quinidine is a strong perturber of acidic phospholipid bilayer order and fluidity","volume":"692","author":"Surewicz","year":"1982","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"1","key":"10.1016\/j.jconrel.2019.11.027_bb0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0005-2736(87)90237-9","article-title":"Quinidine and melittin both decrease the fluidity of liver plasma membranes and both inhibit hormone-stimulated adenylate cyclase activity","volume":"899","author":"Needham","year":"1987","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"1","key":"10.1016\/j.jconrel.2019.11.027_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0168-3659(03)00163-9","article-title":"Relationships between the hydrophilic\u2013lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines","volume":"90","author":"Lo","year":"2003","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2019.11.027_bb0170","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1529\/biophysj.106.089581","article-title":"Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity","volume":"91","author":"Meier","year":"2006","journal-title":"Biophys. J."},{"issue":"22","key":"10.1016\/j.jconrel.2019.11.027_bb0175","doi-asserted-by":"crossref","first-page":"12897","DOI":"10.1074\/jbc.271.22.12897","article-title":"The role of passive Transbilayer drug movement in multidrug resistance and its modulation","volume":"271","author":"Eytan","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8020012","article-title":"Evaluation of P-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay","volume":"8","author":"Jouan","year":"2016","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.jconrel.2019.11.027_bb0185","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/dmd.105.008615","article-title":"In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates","volume":"34","author":"Rautio","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jconrel.2019.11.027_bb0190","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0022-3565(24)37795-X","article-title":"Differential effects of S6 mutations on binding of quinidine and 4-Aminopyridine to rat isoform of Kv1.4: common site but different factors in determining Blockers\u2019 binding affinity","volume":"287","author":"Zhang","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2019.11.027_bb0195","doi-asserted-by":"crossref","DOI":"10.1097\/01.ccm.0000510449.80675.53","article-title":"High-dose intravenous quinidine gluconate results in delayed cardiac toxicity","volume":"44","author":"Patel","year":"2016","journal-title":"Crit. Care Med."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0200","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jacc.2012.02.052","article-title":"Multifocal ectopic Purkinje-related premature contractions: a new SCN5A-related cardiac Channelopathy","volume":"60","author":"Laurent","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.jconrel.2019.11.027_bb0205","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1440-1681.1996.tb01187.x","article-title":"Differential effects of antiarrhythmic agents on post-pause repolarization in cardiac Purkinje fibers","volume":"23","author":"Wyse","year":"1996","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0210","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-3565(24)29254-5","article-title":"Mechanism of Pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization","volume":"299","author":"Batrakova","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0215","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-3565(24)38781-6","article-title":"Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies","volume":"296","author":"Batrakova","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2019.11.027_bb0220","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1023\/A:1018873702411","article-title":"Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers","volume":"16","author":"Miller","year":"1999","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2019.11.027_bb0225","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1432-1033.1995.tb20352.x","article-title":"Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterationsin membrane fluidity leading to increased membrane permeability","volume":"228","author":"Drori","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0169-409X(02)00176-X","article-title":"Pluronic\u00ae block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier","volume":"55","author":"Kabanov","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2019.11.027_bb0235","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/jpet.102.043307","article-title":"Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells","volume":"304","author":"Batrakova","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2019.11.027_bb0240","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0026-895X(25)13330-0","article-title":"Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells","volume":"33","author":"Zamora","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0245","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2016.10.024","article-title":"Evading P-glycoprotein mediated-efflux chemoresistance using solid lipid nanoparticles","volume":"110","author":"Cavaco","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2019.11.027_bb0250","first-page":"1","article-title":"Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer","author":"Ahmad","year":"2017","journal-title":"Artificial Cells Nanomed. Biotechnol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919306868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919306868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:47:57Z","timestamp":1759160877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919306868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":50,"alternative-id":["S0168365919306868"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.11.027","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}